Human gut microbiome and metabolite dynamics under simulated microgravity

Gut Microbes. 2023 Dec;15(2):2259033. doi: 10.1080/19490976.2023.2259033. Epub 2023 Sep 25.

Abstract

The Artificial Gravity Bed Rest - European Space Agency (AGBRESA) study was the first joint bed rest study by ESA, DLR, and NASA that examined the effect of simulated weightlessness on the human body and assessed the potential benefits of artificial gravity as a countermeasure in an analog of long-duration spaceflight. In this study, we investigated the impact of simulated microgravity on the gut microbiome of 12 participants during a 60-day head-down tilt bed rest at the :envihab facilities. Over 60 days of simulated microgravity resulted in a mild change in the gut microbiome, with distinct microbial patterns and pathway expression in the feces of the countermeasure group compared to the microgravity simulation-only group. Additionally, we found that the countermeasure protocols selectively increased the abundance of beneficial short-chain fatty acids in the gut, such as acetate, butyrate, and propionate. Some physiological signatures also included the modulation of taxa reported to be either beneficial or opportunistic, indicating a mild adaptation in the microbiome network balance. Our results suggest that monitoring the gut microbial catalog along with pathway clustering and metabolite profiling is an informative synergistic strategy to determine health disturbances and the outcome of countermeasure protocols for future space missions.

Keywords: AGBRESA; Gut microbiome; SCFA; bed rest study; functional analysis; gut metabolites; metaproteomics; microgravity; spaceflight.

Plain language summary

The future of spaceflight will involve missions beyond the International Space Station or the Moon and astronaut’s health will be challenged by a harsh space environment for longer periods. In the last decade, the intestine has gained importance in dictating overall physiology and we explore it as an additional indicator of health during our ground-based bed rest study simulating microgravity for 60 days. Through the analysis of fecal proteins, we compile the catalog of microbes colonizing the gut of the 12 participants along with the implicated biological activity of the proteins and another 9 lipid analytes. We found specific microbes associated with recovery or healthy status in our subjects to be increased during spaceflight countermeasure conditions and inverse observations in subjects subjected to perilous spaceflight simulation. Our approach improves the functional characterization of the gut by the use of noninvasive methodology correlating the microbial composition of human stool samples with physiological status.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bed Rest
  • Gastrointestinal Microbiome*
  • Head-Down Tilt / physiology
  • Humans
  • Space Flight*
  • Weightlessness*

Grants and funding

The DLR research team received funding from the following DLR grants: ISS LIFE (Program RF-FuW, Grant#475). The study was funded by the German Aerospace Center, the European Space Agency (contract number 4000113871/15/NL/PG) and the National Aeronautics and Space Administration (contract number 80JSC018P0078), and performed at the :envihab research facility of the DLR Institute of Aerospace Medicine. A.R.N. was supported by the DLR/DAAD Research Fellowship [57575486]. These results will be included in the PhD thesis of A. H.